Vertex Pharmaceuticals Incorporated announced that effective January 20, 2015, Kenneth L. Horton transitioned from his role as the executive vice president and chief legal officer to a role as special counsel to chief executive officer. In his new role, Horton is no longer an executive officer of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
488.7 USD | -0.69% |
|
+2.99% | +20.12% |
Jul. 11 | Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $455 From $402 | MT |
Jul. 09 | RBC Raises Price Target on Vertex Pharmaceuticals to $431 From $421, Keeps Sector Perform Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B | |
+147.53% | 12.37B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Incorporated Announces Executive Changes